Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Pharma official: Expect “substantial” revision of ICH stability and specification guidelines
Pharma official: Expect “substantial” revision of ICH stability and specification guidelines
RAPS.org
ICH
Europe
Flag link:
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
Fierce Pharma
GSK
Merck
Keytruda
Jemperli
cancer
Flag link:
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Endpoints
Merck KGaA
Pfizer
cancer
Bavencio
Flag link:
FDA details plan to end emergency use authorizations for devices
FDA details plan to end emergency use authorizations for devices
Medtech Dive
devices
Medtech
FDA
COVID-19
Emergency Use Authorization
Flag link:
Proposed FDA guidelines to strengthen oversight on accelerated approval cancer drugs
Proposed FDA guidelines to strengthen oversight on accelerated approval cancer drugs
Medical Marketing and Media
FDA
clinical trials
cancer
oncology
accelerated approvals
Flag link:
Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report
Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report
Endpoints
Eli Lilly
Ireland
drug manufacturing
Flag link:
PharmaBlock Opens New R&D Facility in Pennsylvania ——Expanding Capacity to Deliver GMP Projects
PharmaBlock Opens New R&D Facility in Pennsylvania ——Expanding Capacity to Deliver GMP Projects
CP Wire
PharmaBlock
R&D
Pennsylvania
CDMOs
Flag link:
PharmaBlock Opens New R&D Facility in Pennsylvania ——Expanding Capacity to Deliver GMP Projects
PharmaBlock
R&D
Pennsylvania
CDMOs
Flag link:
March 27 2023 - Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Flag link:
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Novartis
clinical trials
Kisqali
breast cancer
Flag link:
With one of biotech's largest private rounds in a year, ArriVent enters PhIII
With one of biotech's largest private rounds in a year, ArriVent enters PhIII
Endpoints
ArriVent Biopharma
funding
solid tumors
Flag link:
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Fierce Pharma
Novo Nordisk
Rybelsus
diabetes
clinical trials
Eli Lilly
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
Biopharma Reporter
BioNTech
earnings
COVID-19
vaccines
Flag link:
FDA floats oncology authorization shake-up, pitching 'one-trial' model for accelerated and full approval
FDA floats oncology authorization shake-up, pitching 'one-trial' model for accelerated and full approval
Fierce Biotech
FDA
oncology
regulatory
Flag link:
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn
BioSpace
BrainStorm Cell Therapeutics
NurOwn
ALS
FDA
Flag link:
Vertex flexes its dealmaking muscle
Vertex flexes its dealmaking muscle
EP Vantage
Vertex Pharmaceuticals
Entrada Therapeutics
Tevard Biosciences
Duchenne Muscular Dystrophy
Flag link:
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
BioSpace
Relmada Therapeutics
REL-1017
major depressive disorder
Flag link:
CVS To Close Signify Health Deal, Launching A National In-Home Care Business
CVS To Close Signify Health Deal, Launching A National In-Home Care Business
Forbes
CVS Health
M&A
Signify Health
home healthcare
Flag link:

Pages